2003/8/159 BOCS (Formely FBCS) 31/12/2020
2001-11-162 TEAM 01/01/2019
1903782 A phase 2 study of LAG525 with PDR001 and carboplatin in advanced TNBC 07/02/2021
1902773 DANTE (Duration of Anti-PD1 therapy for melanoma) 28/02/2023
1902765 Ribociclib Non-Interventional Study 15/08/2022
1901755 Ferring 000108 PRONOUNCE 15/04/2022
1901749 CALLS – CML and ALL Low Level Mutation Study 31/12/2018
1901747 MUK nine b: OPTIMUM 31/12/2021
1901746 MUK nine a: screening study 15/01/2024
1812732 Daiichi Sankyo DS8201-A-U201 (DS-8201a) 30/04/2019
1812731 B-AHEAD3: Breast Activity and Healthy Eating After Diagnosis 3 28/02/2020
1810700 PLATO – PersonaLising Anal cancer radioTherapy dOse 31/01/2022
1810695 OPINION, Olaparib Maintenance Monotherapy Ovarian Cancer. 30/09/2020
1805632 National Lung Matrix: Multi-Drug Phase II trial in NSC Lung Cancer 01/10/2021
1805629 ROVA-T Maintenance in SCLC (MERU) 30/04/2020
1805626 LCH­-IV 01/12/2025
1804571 Open Label Study of Relugolix in Men with Advanced Prostate Cancer 30/11/2019
1803566 CTC-STOP 31/01/2021
1802579 PRAN-16-52 Pracinostat in combination with Azacitidine in Adult AML 30/12/2019
1802571 CR UK Stratified Medicine Pilot study 31/12/2020
1712545 CITADEL-202: Safety and Efficacy of INCB050465 in B-Cell Lymphoma 01/06/2020
1712541 Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study 14/03/2019
1712540 CHRONOS-4 25/02/2025
1710507 Niraparib in men with mCRPC and DNA repair anomalies 30/06/2020
1708490 PRIMETIME 24/01/2021
1708470 plasmaMATCH 31/05/2019
1707467 CompLEEment-1 09/11/2020
1706435 Myeloma XII (ACCoRd trial) Version 1.0 31/01/2026
1706433 MUK8 31/12/2018
1704408 DETECT I 01/02/2019
1704403 TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia 31/08/2019
1703398 CANC – 4658 18/09/2021
1703394 IMRiS 30/09/2020
1703390 CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC) 31/12/2020
1702383 CANC 5507 14/06/2019
1702380 CANC 5081 30/08/2019
1702374 Prepare-ABC 01/05/2020
1612350 INCA 30/04/2021
1610318 AML19 09/11/2031
1610314 HART 31/01/2023
1608296 Hartmann’s procedure versus intersphincteric APE: a prospective study 30/06/2019
1607275 DARS 01/06/2020
1605234 EMBARK:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer 30/11/2020
1604237 SelPac 31/12/2018
1604233 CANC – 4039 – Pharmacokinetics of Ramucirumab in Second Line Gastric Adenocarcinoma (JVDB) 01/05/2022
1603225 ACELARATE 31/12/2020
1603223 CANC – 4556 31/03/2019
1602212 CompARE Trial 01/11/2020
1601206 MelMarT 31/12/2026
1601198 Add-Aspirin Trial 15/08/2030
1512190 NCRN – 3312 – MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer 15/06/2021
1508136 MCL Biobank Observational Study 30/10/2019
1507112 STAR Standard vs Modified Drug Therapy in Renal Cancer 20/02/2019
1503071 FLAIR 30/01/2020
1502056 The Molecular Investigation of Unexplained Anaemias 30/11/2023
1411013 FOCUS 4 01/04/2020
1408976 DESTINY 20/09/2019
1407965 De-ESCALaTE HPV 01/01/2022
1406946 NCRN – 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 23/01/2024
1312865 NCRN487 ECHELON-1: A+AVD vs ABVD in first line advanced Hodgkin Lymphoma 11/04/2020
1311856 RAPPER 31/03/2022
1309829 BRF115532 01/01/2030
1305779 IoN 01/02/2019
1301726 UKALL 2011 30/04/2019
1210712 INTERLACE 01/12/2019
1210711 ESPAC-4 31/12/2018
1207674 SEARCH 30/09/2019
1206664 FAST-Forward 31/08/2028
1204623 Aristotle 29/06/2019
1008419 Expression of tumour specific proteins during metastasis 31/08/2020
1002346 IMPACT 31/12/2018
907288 RADICALS (MRC PR10) 01/05/2020
902246 MDSBio 24/06/2021
810202 AVAST-M 01/03/2022
809194 ALTTO – Adjuvant Lapatinib and/or Trastuzumab 01/02/2021